pharma · Unresectable Hepatocellular Carcinoma (HCC) · Unexplained Recurrent Miscarriage and Recurrent Implantation Failure
Zenshine Pharmaceuticals
Nanjing Zenshine Pharmaceuticals
Nanjing Zenshine Pharmaceuticals is a pharma organization headquartered in CN. Primary therapeutic focus areas include Unresectable Hepatocellular Carcinoma (HCC), Unexplained Recurrent Miscarriage and Recurrent Implanta
CN HQ
2018 Founded
12 Employees
NMPA registrant Type
Company details
- Status
- Public
- HQ
- CN
- Founded
- 2018
- Employees
- 12
- Programs
- 8
- Drugs
- 17
- Patents
- 0
TQB2101 for Injection
Phase 1 · small molecule · Advanced Hematologic Malignancies
TQB2101 for Injection for Advanced Hematologic Malignancies is a Phase 1 program (small_molecule) at Nanjing Zenshine Pharmaceuticals with 1 ClinicalTrials.gov record(s).
Internal code TQB2101-I-02
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- Nanjing Zenshine Pharmaceuticals
- Phase
- Phase 1
- Modality
- small_molecule
- Indication
- Advanced Hematologic Malignancies
- Status
- active
- Trials
- 1